Drug intelligence / Profile preview

corynanthine

Development stage
Preclinical
Modality
Small Molecules
Administration
Oral, Intravenous
01

Overview

Corynanthine is a naturally occurring yohimban alkaloid found in the Rauvolfia and Corynanthe (including Pausinystalia) genera of plants[1][3][7]. It is one of two diastereoisomers of yohimbine, the other being rauwolscine[1][7]. Corynanthine functions pharmacologically primarily as a selective alpha-1-adrenergic receptor antagonist, showing approximately tenfold higher affinity for these receptors than for alpha-2-adrenergic receptors[1][5][11]. This contrasts with yohimbine and rauwolscine, which are more selective for the alpha-2-adrenergic receptor. The result is that corynanthine is not a stimulant, but instead acts as a depressant and is thought to contribute to the antihypertensive effects of certain Rauvolfia extracts[1][5][11]. It also has some reported activity at serotonin receptors[1] and has been shown experimentally to decrease intraocular pressure in animal studies[11][12].

Other names
corynanthinerauhimbineCorynanthinmethyl (16beta,17alpha)-17-hydroxyyohimban-16-carboxylateYohimban-16-carboxylic acid, 17-hydroxy-, methyl ester, (16beta,17alpha)UNII-F5Z7C9RK8UUNII-F-5Z7C9RK8UUNII-F 5Z7C9RK8U483-10-3
02

Targets

ADRA1A (α1A)ADRA2C (α2C)ADRA2A (α2A)

Beyond the preview

Go deeper on corynanthine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on corynanthine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call